290 related articles for article (PubMed ID: 6242555)
1. Abnormalities of fibrinolysis in essential hypertension.
Ettenger MM; MacCarthy EP; Glas-Greenwalt P; Clyne DH; Pollak VE
J Hypertens Suppl; 1984 Dec; 2(3):S175-8. PubMed ID: 6242555
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
4. [Fibrinolytic system in patients with nephrotic syndrome].
Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
[No Abstract] [Full Text] [Related]
5. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Aoki N; Moroi M; Matsuda M; Tachiya K
J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
[TBL] [Abstract][Full Text] [Related]
6. White coat hypertension and haemostatic/fibrinolytic balance disorders.
Makris T; Stavroulakis G; Papadopoulos D; Paizis I; Krespi P; Tsoukala C; Hatzizacharias A; Votteas V
Eur Cytokine Netw; 2006 Jun; 17(2):137-41. PubMed ID: 16840033
[TBL] [Abstract][Full Text] [Related]
7. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome.
Gandrille S; Jouvin MH; Toulon P; Remy P; Fiessinger JN; Roncato M; Moatti N; Aiach M
Thromb Haemost; 1988 Jun; 59(3):445-50. PubMed ID: 3142081
[TBL] [Abstract][Full Text] [Related]
8. Advances in clinical fibrinolysis.
Hessel LW; Kluft C
Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
[TBL] [Abstract][Full Text] [Related]
9. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
[TBL] [Abstract][Full Text] [Related]
10. [The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients].
Sorokin EV; Karpov IuA; Dobrovol'skiĭ AB; Vil'chinskaia MIu; Panchenko EP; Titaeva EV; Kagan-Ponomarev MIa
Ter Arkh; 1996; 68(9):19-23. PubMed ID: 9005605
[TBL] [Abstract][Full Text] [Related]
11. Plasma fibrinolytic system and blood pressure in patients with hypertensive cardiovascular disease treated with reserpine and phenformin.
Worowski K; Prokopowicz J; Gabryelewicz A
Haematologia (Budap); 1970; 4(3):399-403. PubMed ID: 4256949
[No Abstract] [Full Text] [Related]
12. [Fibrinolytic system of blood in patients with hypertensive disease].
Fatkhullaev IF; Agapova LA
Ter Arkh; 1974; 46(6):24-7. PubMed ID: 4279461
[No Abstract] [Full Text] [Related]
13. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312
[TBL] [Abstract][Full Text] [Related]
14. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
17. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
18. Influence of homocysteine on fibrin network lysis.
Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity and protein C in preeclampsia.
Aznar J; Gilabert J; Estellés A; España F
Thromb Haemost; 1986 Jun; 55(3):314-7. PubMed ID: 3092388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
